Oncology
Latest news
826 articles · 20 / page
HBsAg <100 IU/mL Identifies Inactive Chronic HBV Patients with HCC Risk Below Surveillance Threshold
A large Asian cohort study shows serum HBsAg
Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI
Lutetium-177 PSMA Radioligand Therapy Improves Disease Control but Not Yet Overall Survival in mCRPC: A Critical Appraisal of a Six‑RCT Meta-Analysis
A meta-analysis of six randomized trials shows [177Lu]Lu‑PSMA significantly increases PSA and objective responses and reduces risk of radiographic progression, with no significant increase in high‑grade toxicity and no clear overall surviva
Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis
22-year single-center data confirm CRS and HIPEC as safe, effective for PMP, yielding 62% 5-year survival. Prognostic factors, optimized HIPEC regimens, and perioperative management impact outcomes and recurrence.
![[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis](https://news.medxy.ai/wp-content/uploads/2025/11/9d3c0201-d1b3-49f2-a408-3ea3d0347451-600x600.jpg)
[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis
PSMAfore shows that [177Lu]Lu-PSMA-617 given to taxane‑naive, PSMA-positive mCRPC patients delays worsening of health-related quality of life, pain, and first symptomatic skeletal events versus switching AR pathway inhibitors.
Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC
In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.
Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra
Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematologic
Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease
Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but
Abemaciclib plus Abiraterone Fails to Improve rPFS in mCRPC: Lessons from the CYCLONE 2 Phase 3 Trial
The phase 3 CYCLONE 2 trial found that adding the CDK4/6 inhibitor abemaciclib to abiraterone did not significantly prolong radiographic progression‑free survival in men with metastatic castration‑resistant prostate cancer and increased tox
Routine Whole‑Body Imaging Did Not Improve Early Survival in High‑Risk Melanoma: Interim TRIM Trial Analysis
Interim results from the multicentre phase 3 TRIM trial show no survival benefit from adding scheduled whole‑body CT or FDG‑PET‑CT to physical‑examination follow‑up after radical surgery for stage IIB–C and III cutaneous melanoma at median
Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival
Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies
AI-RAPNO: Translating Artificial Intelligence into Reliable Response Assessment for Pediatric Neuro-Oncology
AI-RAPNO synthesizes current AI developments for pediatric brain tumour imaging and provides practical recommendations to improve trustworthiness, generalisability, and clinical implementation of AI-driven response assessment using the RAPN
Vorasidenib Slows Tumour Growth and Reduces Seizures in IDH‑Mutant Grade 2 Glioma — Robust PFS and Preserved Cognition in the INDIGO Phase 3 Trial
In the INDIGO phase 3 trial, vorasidenib markedly prolonged progression‑free survival and time to next intervention, reduced volumetric tumour growth and seizure burden, and preserved quality of life and neurocognitive function in patients
Lower, More Frequent Cisplatin Dosing Substantially Reduces Hearing Loss in Head and Neck Cancer Without Compromising Short‑Term Survival
A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.
Ivonescimab (PD‑1/VEGF bispecific) Plus Chemo Outperforms PD‑1+Chemo in First‑Line Advanced Squamous NSCLC: HARMONi‑6 Results Redefine a Tough Indication
Phase 3 HARMONi‑6: ivonescimab + paclitaxel/carboplatin increased median PFS to 11.1 vs 6.9 months (HR 0.60, P
How Milk Sugar Fuels Immune Cells to Fight Cancer: The Surprising Role of Galactose
New research reveals that galactose from dietary sources like milk reprograms liver metabolism, boosting immune T cell activity to combat tumors by preventing their exhaustion.
Hair Straighteners, Chemical Relaxers, Increase Risk of Non‑Reproductive Cancers
A US cohort study (Sister Study) found that recent use of hair straighteners/chemical relaxers was associated with higher incidence of thyroid cancer, pancreatic cancer, and a possible increase in non‑Hodgkin lymphoma; associations were imp
Patritumab Deruxtecan (HER3-DXd) Shows Promising Activity in Breast Cancer Patients with Active Brain Metastases: Insights from the TUXEDO-3 Phase 2 Trial
The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.
European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile
The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.
Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer
Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.
Browse by specialty
Open language-specific specialty feeds and department pages.